Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus

References

• Zhao L, Li L, Ren H, et al. Association between serum alkaline phosphatase and renal outcome in patients with type 2 diabetes mellitus. Ren Fail. 2020;42(1):818–828.
   PubMed Web of Science ®Google Scholar
• Rawshani A, Rawshani A, Franzen S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407–1418.
   PubMed Web of Science ®Google Scholar
• Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575–584.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics – 2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–e603.
   PubMed Web of Science ®Google Scholar
• Ilyas Z, Chaiban JT, Krikorian A. Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy. Rev Endocr Metab Disord. 2017;18(1):21–28.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao MH, Zuo L, et al. China kidney disease network (CK-NET) 2015 annual data report. Kidney Int Suppl. 2019;9(1):e1–e81.
   Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68(1):228–236.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80(1):93–104.
   PubMed Web of Science ®Google Scholar
• Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (London, England). 2012;380(9854):1662–1673.
   PubMed Web of Science ®Google Scholar
• Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167(11):1130–1136.
   PubMed Web of Science ®Google Scholar
• Preiss D, Kristensen SL. The new pooled cohort equations risk calculator. Can J Cardiol. 2015;31(5):613–619.
   PubMed Web of Science ®Google Scholar
• Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311(14):1406–1415.
   PubMed Web of Science ®Google Scholar
• Mora S, Wenger NK, Cook NR, et al. Evaluation of the pooled cohort risk equations for cardiovascular risk prediction in a multiethnic cohort from the women's health initiative. JAMA Intern Med. 2018;178(9):1231–1240.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2017 abridged for primary care providers. Clin Diabet. 2017;35(1):5–26.
   PubMedGoogle Scholar
• Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556–563.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–S73.
   PubMed Web of Science ®Google Scholar
• Morris AA, Ko Y-A, Hutcheson SH, et al. Race/ethnic and sex differences in the association of atherosclerotic cardiovascular disease risk and healthy lifestyle behaviors. JAHA. 2018;7(10):e008250.
   Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472.
   PubMed Web of Science ®Google Scholar
• Bajaj A, Xie D, Cedillo-Couvert E, et al. Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD. Am J Kidney Dis. 2019;73(6):827–836.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87.
   PubMed Web of Science ®Google Scholar
• Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2019;jc.2019-01338. DOI:10.1210/jc.2019-01338
   PubMedGoogle Scholar
• Mons U, Müezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. Br Med J. 2015;350:h1551.
   PubMedGoogle Scholar
• Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013;15(3):340.
   PubMed Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet (London, England). 2010;375(9731):2073–2081.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet (London, England). 2011;377(9784):2181–2192.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.
   PubMed Web of Science ®Google Scholar
• Łukawska E, Polcyn-Adamczak M, Niemir ZI. The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med. 2018;18(3):297–318.
   PubMed Web of Science ®Google Scholar
• Chia YC, Lim HM, Ching SM. Validation of the pooled cohort risk score in an Asian population – a retrospective cohort study. BMC Cardiovasc Disord. 2014;14:163.
   PubMed Web of Science ®Google Scholar
• Tyson CC, Smith PJ, Sherwood A, et al. Association between normal or mildly reduced kidney function, cardiovascular risk and biomarkers for atherosclerosis: results from the ENCORE trial. Clin Kidney J. 2017;10(5):666–671.
   PubMed Web of Science ®Google Scholar
• Lu J, Mu Y, Su Q, et al. Reduced kidney function is associated with cardiometabolic risk factors, prevalent and predicted risk of cardiovascular disease in Chinese adults: results from the REACTION study. JAHA. 2016;5(7):e003328.
   Google Scholar
• Moon BS, Kim J, Kim JH, et al. Eligibility for statin treatment in Korean subjects with reduced renal function: an observational study. Endocrinol Metab. 2016;31(3):402–409.
   Google Scholar
• Papademetriou V, Lovato L, Doumas M, et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015;87(3):649–659.
   PubMed Web of Science ®Google Scholar
• Rahman M, Ford CE, Cutler JA, et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. CJASN. 2012;7(6):989–1002.
   PubMed Web of Science ®Google Scholar
• Hillege HL, van Gilst WH, van Veldhuisen DJ, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J. 2003;24(5):412–420.
   PubMed Web of Science ®Google Scholar
• van Dokkum RP, Eijkelkamp WB, Kluppel AC, et al. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol. 2004;15(12):3103–3110.
   PubMed Web of Science ®Google Scholar
• Berton G, Cordiano R, Palmieri R, et al. Microalbuminuria during acute myocardial infarction: a strong predictor for 1-year mortality. Eur Heart J. 2001;22(16):1466–1475.
   PubMed Web of Science ®Google Scholar
• Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabet. 2017;9(5):434–449.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139.
   PubMed Web of Science ®Google Scholar
• Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009;53(5 Suppl):S35–S42.
   PubMed Web of Science ®Google Scholar
• He Z, King GL. Microvascular complications of diabetes. Endocrinol Metab Clin North Am. 2004;33(1):215xii.
   Web of Science ®Google Scholar
• Thomas JE, Foody JM. The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy. J Cardiometab Syndr. 2007;2(2):108–113.
   PubMedGoogle Scholar
• Bhattacharyya S, Marinic TE, Krukovets I, et al. Cell type-specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose. J Biol Chem. 2008;283(9):5699–5707.
   PubMed Web of Science ®Google Scholar
• Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100(2):158–173.
   PubMed Web of Science ®Google Scholar
• Suetsugu M, Takebayashi K, Aso Y. Association between diabetic microangiopathy and vascular endothelial function evaluated by flow-mediated vasodilatation in patients with type 2 diabetes. Int J Clin Pract. 2007;61(6):920–926.
   PubMed Web of Science ®Google Scholar